{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:19:35Z","timestamp":1783423175660,"version":"3.54.6"},"reference-count":70,"publisher":"IMR Press","issue":"6","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Given the multi-organ involvement of transthyretin (ATTR) amyloidosis, associated symptoms such as peripheral neuropathy, biceps tendon rupture, lumbar stenosis, and bilateral carpal tunnel syndrome can develop concurrently with cardiac disease or even precede the cardiac diagnosis by up to a decade. Screening of tissue obtained opportunistically during an otherwise indicated procedure or diagnostic test has shown promise for the early identification of nascent cardiac amyloidosis (CA) in patients who might otherwise remain undiagnosed for years. This review aims to: (1) briefly summarize the cardiac and non-cardiac manifestations of transthyretin cardiomyopathy (ATTR-CM) that may raise clinical suspicion for the disease; (2) discuss tissue-based screening within contemporary ATTR-CM diagnostic pathways; (3) describe the diagnostic yield and management challenges of tissue screening, with a focus on early detection; (4) examine the treatment and surveillance implications of tissue screening in both symptomatic and asymptomatic individuals. Multidisciplinary collaboration (e.g., partnerships between hand surgery centers and amyloid centers) and criteria-based screening of specimens obtained during noncardiac and cardiac surgery may offer an effective strategy for identifying patients earlier in the associated disease course. However, given the variable diagnostic yield, the significant anxiety associated with comprehensive evaluation for ATTR-CM, and the potentially high cost of treating CA with one of the three therapies approved by the Food and Drug Administration (FDA), further refinement of screening criteria and additional investigation into the impact of early treatment on disease trajectory and outcomes are needed.<\/jats:p>","DOI":"10.31083\/rcm50854","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:06:15Z","timestamp":1783422375000},"source":"Crossref","is-referenced-by-count":0,"title":["Tissue Screening and Diagnosis of Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.31083","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3779-1622","authenticated-orcid":true,"given":"Ryan","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8196-2919","authenticated-orcid":true,"given":"Harsh","family":"Patolia","sequence":"additional","affiliation":[{"name":"George and Linda Kaufman Center for Heart Failure and Recovery, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neehal","family":"Shukla","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-6090","authenticated-orcid":true,"given":"Judah","family":"Rajendran","sequence":"additional","affiliation":[{"name":"George and Linda Kaufman Center for Heart Failure and Recovery, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8587-2881","authenticated-orcid":true,"given":"Michel Chedid","family":"El Helou","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianne","family":"Agdamag","sequence":"additional","affiliation":[{"name":"George and Linda Kaufman Center for Heart Failure and Recovery, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH 44195, USA"},{"name":"Amyloidosis Center, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry D.","family":"Estep","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic Florida, Weston, FL 33331, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3576-3660","authenticated-orcid":true,"given":"Andres Carmona","family":"Rubio","sequence":"additional","affiliation":[{"name":"George and Linda Kaufman Center for Heart Failure and Recovery, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH 44195, USA"},{"name":"Amyloidosis Center, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7251-3003","authenticated-orcid":true,"given":"Mazen","family":"Hanna","sequence":"additional","affiliation":[{"name":"George and Linda Kaufman Center for Heart Failure and Recovery, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH 44195, USA"},{"name":"Amyloidosis Center, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6754-3670","authenticated-orcid":true,"given":"Trejeeve","family":"Martyn","sequence":"additional","affiliation":[{"name":"George and Linda Kaufman Center for Heart Failure and Recovery, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH 44195, USA"},{"name":"Amyloidosis Center, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Donnelly JP, Hanna M. Cardiac amyloidosis: An update on diagnosis and treatment. Cleveland Clinic Journal of Medicine. 2017; 84: 12\u201326.","DOI":"10.3949\/ccjm.84.s3.02"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal. 2021; 42: 1554\u20131568.","DOI":"10.1093\/eurheartj\/ehab072"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017; 135: 1357\u20131377.","DOI":"10.1161\/CIRCULATIONAHA.116.024438"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, et al. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC. Heart Failure. 2019; 7: 709\u2013716.","DOI":"10.1016\/j.jchf.2019.04.010"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, et al. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circulation. Heart Failure. 2019; 12: e006075.","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Karam C, Moffit C, Summers C, Merkel MP, Kochman FM, Weijers L, et al. The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvement. Orphanet Journal of Rare Diseases. 2024; 19: 419.","DOI":"10.1186\/s13023-024-03407-3"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Vogel J, Jura S, Buehing F, Wernhart S, Carpinteiro A, Rassaf T, Michel L. Delays in diagnosis and treatment initiation of ATTR cardiac amyloidosis: a real-world data analysis. European Heart Journal. 2024; 45: ehae666.774.","DOI":"10.1093\/eurheartj\/ehae666.774"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Writing Committee, Kittleson MM, Ambardekar AV, Cheng RK, Griffin JM, Maurer MS, et al. Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance. Journal of the American College of Cardiology. 2026; 87: 549\u2013565.","DOI":"10.1016\/j.jacc.2025.09.004"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Westin O, Fosb\u00f8l EL, Maurer MS, Leicht BP, Hasbak P, Mylin AK, et al. Screening for Cardiac Amyloidosis 5 to 15 Years After Surgery for Bilateral Carpal Tunnel Syndrome. Journal of the American College of Cardiology. 2022; 80: 967\u2013977.","DOI":"10.1016\/j.jacc.2022.06.026"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Gonz\u00e1lez-L\u00f3pez E, L\u00f3pez-Sainz \u00c1, Garcia-Pavia P. Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope. Revista Espanola De Cardiologia (English Ed.). 2017; 70: 991\u20131004.","DOI":"10.1016\/j.rec.2017.05.036"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. European Heart Journal. 2018; 39: 2799\u20132806.","DOI":"10.1093\/eurheartj\/ehx589"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Nitsche C, Ioannou A, Patel RK, Razvi Y, Porcari A, Rauf MU, et al. Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis. European Journal of Heart Failure. 2024; 26: 2008\u20132012.","DOI":"10.1002\/ejhf.3354"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Damy T, Kristen AV, Suhr OB, Maurer MS, Plant\u00e9-Bordeneuve V, Yu CR, et al. Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). European Heart Journal. 2022; 43: 391\u2013400.","DOI":"10.1093\/eurheartj\/ehz173"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. The New England Journal of Medicine. 2024; 390: 132\u2013142.","DOI":"10.1056\/NEJMoa2305434"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, et al. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. The New England Journal of Medicine. 2025; 392: 33\u201344.","DOI":"10.1056\/NEJMoa2409134"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016; 133: 2404\u20132412.","DOI":"10.1161\/CIRCULATIONAHA.116.021612"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. Circulation. Cardiovascular Imaging. 2021; 14: e000029.","DOI":"10.1161\/HCI.0000000000000029"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Maleszewski JJ. Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology. 2015; 24: 343\u2013350.","DOI":"10.1016\/j.carpath.2015.07.008"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Leguit RJ, Vink A, de Jonge N, Minnema MC, Oerlemans MIF. Endomyocardial biopsy with co-localization of a lymphoplasmacytic lymphoma and AL amyloidosis. Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology. 2021; 53: 107348.","DOI":"10.1016\/j.carpath.2021.107348"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Kiamanesh O, Toma M. The State of the Heart Biopsy: A Clinical Review. CJC Open. 2020; 3: 524\u2013531.","DOI":"10.1016\/j.cjco.2020.11.017"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Cohen OC, Sharpley F, Gilbertson JA, Wechalekar AD, Sachchithanantham S, Mahmood S, et al. The value of screening biopsies in light-chain (AL) and transthyretin (ATTR) amyloidosis. European Journal of Haematology. 2020; 105: 352\u2013356.","DOI":"10.1111\/ejh.13458"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Paulsson Rokke H, Sadat Gousheh N, Westermark P, Suhr OB, Anan I, Ihse E, et al. Abdominal fat pad biopsies exhibit good diagnostic accuracy in patients with suspected transthyretin amyloidosis. Orphanet Journal of Rare Diseases. 2020; 15: 278.","DOI":"10.1186\/s13023-020-01565-8"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Quarta CC, Gonzalez-Lopez E, Gilbertson JA, Botcher N, Rowczenio D, Petrie A, et al. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. European Heart Journal. 2017; 38: 1905\u20131908.","DOI":"10.1093\/eurheartj\/ehx047"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Azzam M, Kawtharany H, Nazzal J, Kukreti V, Seftel MD, Alkhader A, et al. Diagnostic test accuracy of fat pad sampling and bone marrow biopsies in the diagnosis of AL amyloidosis: a systematic review and meta-analysis. Blood. 2024; 144: 6896.","DOI":"10.1182\/blood-2024-210641"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Mercan R, B\u0131t\u0131k B, Tezcan ME, Kaya A, Tufan A, Ozturk MA, et al. Minimally invasive minor salivary gland biopsy for the diagnosis of amyloidosis in a rheumatology clinic. ISRN Rheumatology. 2014; 2014: 354648.","DOI":"10.1155\/2014\/354648"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Hachulla E, Janin A, Flipo RM, Sa\u00efle R, Facon T, Bataille D, et al. Labial salivary gland biopsy is a reliable test for the diagnosis of primary and secondary amyloidosis. A prospective clinical and immunohistologic study in 59 patients. Arthritis and Rheumatism. 1993; 36: 691\u2013697.","DOI":"10.1002\/art.1780360518"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Merlini G, Dispenzieri A, Sanchorawala V, Sch\u00f6nland SO, Palladini G, Hawkins PN, et al. Systemic immunoglobulin light chain amyloidosis. Nature Reviews. Disease Primers. 2018; 4: 38.","DOI":"10.1038\/s41572-018-0034-3"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Muller SA, Peir\u00f3-Aventin B, Biagioni G, Tini G, Saturi G, Kronberger C, et al. Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis. European Journal of Heart Failure. 2024; 26: 2025\u20132034.","DOI":"10.1002\/ejhf.3339"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, et al. Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. Journal of the American College of Cardiology. 2018; 72: 2040\u20132050.","DOI":"10.1016\/j.jacc.2018.07.092"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Yanagisawa A, Ueda M, Sueyoshi T, Okada T, Fujimoto T, Ogi Y, et al. Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis. Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc. 2015; 28: 201\u2013207.","DOI":"10.1038\/modpathol.2014.102"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Nativi-Nicolau J, Sarswat N, Fajardo J, Finkel M, Abdulsattar Y, Casta\u00f1o A, et al. Best Practices in Specialized Amyloidosis Centers in the United States: A Survey of Cardiologists, Nurses, Patients, and Patient Advocates. Clinical Medicine Insights. Cardiology. 2021; 15: 11795468211015230.","DOI":"10.1177\/11795468211015230"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Moore ZJ, Rizkalla JM, Weiner J, Lawrence B, Spina N, Spiker R, et al. Transthyretin amyloidosis in spinal canal stenosis: A systematic review. Journal of Orthopaedics. 2024; 53: 133\u2013139.","DOI":"10.1016\/j.jor.2024.02.047"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Iida T, Yamano H, Nakase H. Systemic amyloidosis with gastrointestinal involvement: Diagnosis from endoscopic and histological views. Journal of Gastroenterology and Hepatology. 2018; 33: 583\u2013590.","DOI":"10.1111\/jgh.13996"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Tang MJ, Tay TY, Gibbs S, Niewiadomski O. Amyloidosis for the Gastroenterologist: A Comprehensive Systematic Review of Diagnosis and Management of Gastrointestinal Manifestations. Journal of Gastroenterology and Hepatology. 2025; 40: 2842\u20132856.","DOI":"10.1111\/jgh.70083"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Khedraki R, El-Roumi J, Allende D, Ives L, Garber A, RubioTapia A, et al. Gastrointestinal Amyloid Screening Study (GASS): is screening for amyloid in the gastrointestinal tract useful? Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 2024; 31: 241\u2013243.","DOI":"10.1080\/13506129.2024.2347493"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Cesp\u00f3n-Fern\u00e1ndez M, Escalona-Canal EJ, S\u00e1nchez-Ramos J, Raposeiras-Roub\u00edn S, Abdulkader-Sande S, Cobas-Paz RJ, et al. Amyloid deposits in prostate biopsy as an opportunity to diagnose early cardiac amyloidosis. Journal of Geriatric Cardiology : JGC. 2025; 22: 169\u2013177.","DOI":"10.26599\/1671-5411.2025.01.007"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Katzianer DS, Kwon DH, Thamilarasan M, Finet JE, Jaber W, Desai M, et al. Prevalence of amyloid deposition in patients undergoing surgical myectomy for presumed hypertrophic cardiomyopathy. Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology. 2026; 80: 107779.","DOI":"10.1016\/j.carpath.2025.107779"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Maurer MS, Smiley D, Simsolo E, Remotti F, Bustamante A, Teruya S, et al. Analysis of lumbar spine stenosis specimens for identification of amyloid. Journal of the American Geriatrics Society. 2022; 70: 3538\u20133548.","DOI":"10.1111\/jgs.17976"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Nakagawa M, Sekijima Y, Yazaki M, Tojo K, Yoshinaga T, Doden T, et al. Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 2016; 23: 58\u201363.","DOI":"10.3109\/13506129.2015.1135792"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Stein K, St\u00f6rkel S, Linke RP, Goebel HH. Chemical heterogeneity of amyloid in the carpal tunnel syndrome. Virchows Archiv. A, Pathological Anatomy and Histopathology. 1987; 412: 37\u201345.","DOI":"10.1007\/BF00750729"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Plant\u00e9-Bordeneuve V, Said G. Familial amyloid polyneuropathy. The Lancet. Neurology. 2011; 10: 1086\u20131097.","DOI":"10.1016\/S1474-4422(11)70246-0"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Bastian FO. Amyloidosis and the carpal tunnel syndrome. American Journal of Clinical Pathology. 1974; 61: 711\u2013717.","DOI":"10.1093\/ajcp\/61.5.711"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Milandri A, Farioli A, Gagliardi C, Longhi S, Salvi F, Curti S, et al. Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies. European Journal of Heart Failure. 2020; 22: 507\u2013515.","DOI":"10.1002\/ejhf.1742"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Rubin J, Alvarez J, Teruya S, Castano A, Lehman RA, Weidenbaum M, et al. Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier? Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 2017; 24: 226\u2013230.","DOI":"10.1080\/13506129.2017.1375908"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Sperry BW, Khedraki R, Gabrovsek A, Donnelly JP, Kilpatrick S, Shapiro D, et al. Cardiac Amyloidosis Screening at Trigger Finger Release Surgery. The American Journal of Cardiology. 2021; 160: 96\u201398.","DOI":"10.1016\/j.amjcard.2021.08.049"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Westermark P, Westermark GT, Suhr OB, Berg S. Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis. Upsala Journal of Medical Sciences. 2014; 119: 223\u2013228.","DOI":"10.3109\/03009734.2014.895786"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Russell A, Hahn C, Chhibber S, Korngut L, Fine NM. Utility of Neuropathy Screening for Wild-Type Transthyretin Amyloidosis Patients. The Canadian Journal of Neurological Sciences. Le Journal Canadien des Sciences Neurologiques. 2021; 48: 607\u2013615.","DOI":"10.1017\/cjn.2020.271"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Bussi\u00e8res A, Cancelliere C, Ammendolia C, Comer CM, Zoubi FA, Ch\u00e2tillon CE, et al. Non-Surgical Interventions for Lumbar Spinal Stenosis Leading To Neurogenic Claudication: A Clinical Practice Guideline. The Journal of Pain. 2021; 22: 1015\u20131039.","DOI":"10.1016\/j.jpain.2021.03.147"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Geller HI, Singh A, Alexander KM, Mirto TM, Falk RH. Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis. JAMA. 2017; 318: 962\u2013963.","DOI":"10.1001\/jama.2017.9236"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Griffin TC, Samsill BA, Kruse LM, Mosiman SJ, Salyapongse AN, Summers LN, et al. Prevalence of amyloid deposition in distal biceps tendon ruptures: a retrospective review of intraoperative biopsy. JSES Reviews, Reports, and Techniques. 2025; 5: 1198\u20131201.","DOI":"10.1016\/j.xrrt.2025.08.008"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Baylor JL, Nester JR, Olsen HP, Pallis M, Akoon A, Grandizio LC. Prevalence of Amyloid Deposition in Patients Undergoing Surgical Repair of Traumatic Distal Biceps Tendon Ruptures. Journal of Hand Surgery Global Online. 2022; 4: 344\u2013347.","DOI":"10.1016\/j.jhsg.2022.08.008"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Writing Committee, Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2023; 81: 1076\u20131126.","DOI":"10.1016\/j.jacc.2022.11.022"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Obici L, Suhr OB. Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis. Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society. 2019; 29: 55\u201363.","DOI":"10.1007\/s10286-019-00628-6"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Fritz CDL, Blaney E. Evaluation and Management Strategies for GI Involvement with Amyloidosis. The American Journal of Medicine. 2022; 135 Suppl 1: S20\u2013S23.","DOI":"10.1016\/j.amjmed.2022.01.008"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Wixner J, Karling P, Rydh A, H\u00f6rnsten R, Wiklund U, Anan I, et al. Gastric emptying in hereditary transthyretin amyloidosis: the impact of autonomic neuropathy. Neurogastroenterology and Motility. 2012; 24: 1111\u2013e568.","DOI":"10.1111\/j.1365-2982.2012.01991.x"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Wixner J, Mundayat R, Karayal ON, Anan I, Karling P, Suhr OB, et al. THAOS: gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease. Orphanet Journal of Rare Diseases. 2014; 9: 61.","DOI":"10.1186\/1750-1172-9-61"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Ueda M, Horibata Y, Shono M, Misumi Y, Oshima T, Su Y, et al. Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study. Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc. 2011; 24: 1533\u20131544.","DOI":"10.1038\/modpathol.2011.117"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Gonz\u00e1lez-Duarte A, Berk JL, Quan D, Mauermann ML, Schmidt HH, Polydefkis M, et al. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Journal of Neurology. 2020; 267: 703\u2013712.","DOI":"10.1007\/s00415-019-09602-8"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. The New England Journal of Medicine. 2018; 379: 11\u201321.","DOI":"10.1056\/NEJMoa1716153"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Ichimata S, Hata Y, Yoshida K, Hirabayashi K, Nishida N. Exploring the usefulness of prostate tissue in diagnosing transthyretin amyloidosis and predicting cardiac outcomes: an autopsy-based study. Pathology. 2025; 57: 701\u2013707.","DOI":"10.1016\/j.pathol.2025.02.007"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Masri A, Chen Y, Colavecchia AC, Benjumea D, Crowley A, Jhingran P, et al. Coexisting Calcific Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Real-World Evaluation of Clinical Characteristics and Outcomes. Journal of the American Heart Association. 2025; 14: e033251.","DOI":"10.1161\/JAHA.123.033251"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Sperry BW. Coprevalence of Amyloidosis and Aortic Stenosis: When to Screen and Who to Treat? Journal of the American Heart Association. 2025; 14: e038279.","DOI":"10.1161\/JAHA.124.038279"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Roberts WC, Everett BP, Won VS, Kondapalli N. Diagnostic Usefulness of Histological Examination of the Left Ventricular \"Core\" Excised to Insert a Left Ventricular Assist Device in Patients With Severe Heart Failure. The American Journal of Cardiology. 2020; 137: 71\u201376.","DOI":"10.1016\/j.amjcard.2020.09.038"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2022; 79: e263\u2013e421.","DOI":"10.1016\/j.jacc.2021.12.012"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. The New England Journal of Medicine. 2018; 379: 1007\u20131016.","DOI":"10.1056\/NEJMoa1805689"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Lee A. Acoramidis: First Approval. Drugs. 2025; 85: 833\u2013837.","DOI":"10.1007\/s40265-025-02159-z"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Witteles RM, Garcia-Pavia P, Damy T, Grogan M, Sheikh FH, Morbach C, et al. Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B. Journal of the American College of Cardiology. 2025.  (online ahead of print)","DOI":"10.1016\/j.jacc.2025.04.008"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Hanna M, Ruberg FL, Maurer MS, Dispenzieri A, Dorbala S, Falk RH, et al. Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis: JACC Review Topic of the Week. Journal of the American College of Cardiology. 2020; 75: 2851\u20132862.","DOI":"10.1016\/j.jacc.2020.04.022"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Gonzalez-Lopez E, Escobar-Lopez L, Obici L, Saturi G, Bezard M, Saith SE, et al. Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms. JACC. CardioOncology. 2022; 4: 442\u2013454.","DOI":"10.1016\/j.jaccao.2022.07.007"},{"key":"ref70","unstructured":"Eidos Therapeutics, a BridgeBio company. Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant. ClinicalTrials.gov Identifier: NCT06563895. 2024. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06563895 (Accessed: 6 April 2026). https:\/\/clinicaltrials.gov\/study\/NCT06563895"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/6\/10.31083\/RCM50854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:06:58Z","timestamp":1783422418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/6\/10.31083\/RCM50854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"alternative-id":["S1530-6550(26)02384-7"],"URL":"https:\/\/doi.org\/10.31083\/rcm50854","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"article-number":"50854"}}